<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359150</url>
  </required_header>
  <id_info>
    <org_study_id>A3921129</org_study_id>
    <nct_id>NCT01359150</nct_id>
  </id_info>
  <brief_title>A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response
      Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid
      Arthritis receiving CP-690,550 with and Without background Methotrexate
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)</measure>
    <time_frame>Day 64 (End of Study [EOS])</time_frame>
    <description>Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (&gt;=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Satisfactory humoral response to the influenza vaccine was defined as &gt;= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Response to the pneumococcal vaccine (seroconversion) was defined as &gt;= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Responded to Each of the 3 Influenza Antigens</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Response to the influenza vaccine (seroconversion) was defined as &gt;= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of &gt;= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Anti-Influenza Antibody</measure>
    <time_frame>Day 64 (EOS)</time_frame>
    <description>Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2:Placebo CP-690,550 (100 subjects).</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).</description>
    <arm_group_label>Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects</description>
    <arm_group_label>Treatment Group 2:Placebo CP-690,550 (100 subjects).</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must meet the American College of Rheumatology (ACR) classification
             criteria for the diagnosis of RA by satisfying at least four of the seven criteria.

          -  The subject must have active disease at both screening and baseline

        Exclusion Criteria:

          -  History of any documented influenza or pneumococcal infection within the last 3
             months.

          -  Receipt of any vaccine within 1 month prior to the initial study drug administration
             (CP-690,550 or placebo CP-690,550).

          -  If a subject has received an influenza vaccine within 6 months or a pneumococcal
             vaccine within 5 years of initial study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Port Richey</city>
        <state>Florida</state>
        <zip>34668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leominster</city>
        <state>Massachusetts</state>
        <zip>01453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <zip>14760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cieszyn</city>
        <zip>43-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koscian</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-256</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921129&amp;StudyName=A%20Study%20To%20Assess%20the%20Immune%20Response%20Following%20Administration%20Of%20Influenza%20and%20Pneumococcal%20Vaccines%20To%20Subjects%20with%20Rheumatoid%20Arthriti</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <results_first_submitted>January 7, 2013</results_first_submitted>
  <results_first_submitted_qc>February 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2013</results_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
          <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Influenza and Pneumococcal Vaccine</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
          <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Influenza and Pneumococcal Vaccine</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="223"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="10.4"/>
                    <measurement group_id="B2" value="52.2" spread="11.1"/>
                    <measurement group_id="B3" value="52.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants With Background (BG) Methotrexate (MTX) use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With Background MTX use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Background MTX use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)</title>
        <description>Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (&gt;=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (End of Study [EOS])</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)</title>
          <description>Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (&gt;=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" lower_limit="35.224" upper_limit="55.264"/>
                    <measurement group_id="O2" value="68.4" lower_limit="58.196" upper_limit="77.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" lower_limit="19.905" upper_limit="45.243"/>
                    <measurement group_id="O2" value="61.8" lower_limit="47.726" upper_limit="74.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" lower_limit="46.541" upper_limit="76.232"/>
                    <measurement group_id="O2" value="76.7" lower_limit="61.369" upper_limit="88.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)</title>
        <description>Satisfactory humoral response to the influenza vaccine was defined as &gt;= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)</title>
          <description>Satisfactory humoral response to the influenza vaccine was defined as &gt;= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="46.682" upper_limit="66.634"/>
                    <measurement group_id="O2" value="62.2" lower_limit="51.885" upper_limit="71.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="37.29" upper_limit="64.37"/>
                    <measurement group_id="O2" value="58.2" lower_limit="44.106" upper_limit="71.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="48.78" upper_limit="78.132"/>
                    <measurement group_id="O2" value="67.4" lower_limit="51.456" upper_limit="80.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens</title>
        <description>Response to the pneumococcal vaccine (seroconversion) was defined as &gt;= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens</title>
          <description>Response to the pneumococcal vaccine (seroconversion) was defined as &gt;= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use, 1 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="49.63" upper_limit="69.393"/>
                    <measurement group_id="O2" value="69.4" lower_limit="59.265" upper_limit="78.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 14 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="41.844" upper_limit="61.961"/>
                    <measurement group_id="O2" value="61.2" lower_limit="50.849" upper_limit="70.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 18C (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="49.63" upper_limit="69.393"/>
                    <measurement group_id="O2" value="70.4" lower_limit="60.338" upper_limit="79.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 19A (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="23.424" upper_limit="42.337"/>
                    <measurement group_id="O2" value="46.9" lower_limit="36.778" upper_limit="57.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 19F (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="26.086" upper_limit="45.38"/>
                    <measurement group_id="O2" value="56.1" lower_limit="45.732" upper_limit="66.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 23F (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" lower_limit="30.607" upper_limit="50.37"/>
                    <measurement group_id="O2" value="58.2" lower_limit="47.766" upper_limit="68.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 3 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="28.787" upper_limit="48.386"/>
                    <measurement group_id="O2" value="54.1" lower_limit="43.714" upper_limit="64.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 4 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="48.644" upper_limit="68.477"/>
                    <measurement group_id="O2" value="65.3" lower_limit="55.02" upper_limit="74.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 5 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" lower_limit="19.938" upper_limit="38.218"/>
                    <measurement group_id="O2" value="38.8" lower_limit="29.097" upper_limit="49.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 6B (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" lower_limit="26.982" upper_limit="46.386"/>
                    <measurement group_id="O2" value="54.1" lower_limit="43.714" upper_limit="64.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 7F (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="48.644" upper_limit="68.477"/>
                    <measurement group_id="O2" value="65.3" lower_limit="55.02" upper_limit="74.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 9V (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" lower_limit="35.224" upper_limit="55.264"/>
                    <measurement group_id="O2" value="58.2" lower_limit="47.766" upper_limit="68.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="44.084" upper_limit="70.857"/>
                    <measurement group_id="O2" value="61.8" lower_limit="47.726" upper_limit="74.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 14 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="33.985" upper_limit="61.035"/>
                    <measurement group_id="O2" value="56.4" lower_limit="42.322" upper_limit="69.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 18C (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" lower_limit="35.63" upper_limit="62.71"/>
                    <measurement group_id="O2" value="58.2" lower_limit="44.106" upper_limit="71.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 19A (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="10.047" upper_limit="31.911"/>
                    <measurement group_id="O2" value="40" lower_limit="27.023" upper_limit="54.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 19F (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="16.973" upper_limit="41.543"/>
                    <measurement group_id="O2" value="49.1" lower_limit="35.354" upper_limit="62.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 23F (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="14.127" upper_limit="37.761"/>
                    <measurement group_id="O2" value="49.1" lower_limit="35.354" upper_limit="62.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 3 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="14.127" upper_limit="37.761"/>
                    <measurement group_id="O2" value="49.1" lower_limit="35.354" upper_limit="62.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 4 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="38.965" upper_limit="66.015"/>
                    <measurement group_id="O2" value="56.4" lower_limit="42.322" upper_limit="69.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 5 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="16.973" upper_limit="41.543"/>
                    <measurement group_id="O2" value="29.1" lower_limit="17.63" upper_limit="42.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 6B (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" lower_limit="18.429" upper_limit="43.403"/>
                    <measurement group_id="O2" value="47.3" lower_limit="33.653" upper_limit="61.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 7F (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" lower_limit="35.63" upper_limit="62.71"/>
                    <measurement group_id="O2" value="56.4" lower_limit="42.322" upper_limit="69.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 9V (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="21.401" upper_limit="47.065"/>
                    <measurement group_id="O2" value="49.1" lower_limit="35.354" upper_limit="62.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 1 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" lower_limit="46.541" upper_limit="76.232"/>
                    <measurement group_id="O2" value="79.1" lower_limit="63.958" upper_limit="89.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 14 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="42.15" upper_limit="72.343"/>
                    <measurement group_id="O2" value="67.4" lower_limit="51.456" upper_limit="80.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 18C (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="58.055" upper_limit="85.396"/>
                    <measurement group_id="O2" value="86" lower_limit="72.068" upper_limit="94.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 19A (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="33.703" upper_limit="64.226"/>
                    <measurement group_id="O2" value="55.8" lower_limit="39.875" upper_limit="70.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 19F (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="29.644" upper_limit="60.003"/>
                    <measurement group_id="O2" value="65.1" lower_limit="49.073" upper_limit="78.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 23F (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="44.331" upper_limit="74.302"/>
                    <measurement group_id="O2" value="69.8" lower_limit="53.875" upper_limit="82.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 3 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="39.997" upper_limit="70.356"/>
                    <measurement group_id="O2" value="60.5" lower_limit="44.41" upper_limit="75.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 4 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="51.05" upper_limit="79.999"/>
                    <measurement group_id="O2" value="76.7" lower_limit="61.369" upper_limit="88.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 5 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="16.366" upper_limit="44.315"/>
                    <measurement group_id="O2" value="51.2" lower_limit="35.465" upper_limit="66.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 6B (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="29.644" upper_limit="60.003"/>
                    <measurement group_id="O2" value="62.8" lower_limit="46.725" upper_limit="77.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 7F (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="55.685" upper_limit="83.634"/>
                    <measurement group_id="O2" value="76.7" lower_limit="61.369" upper_limit="88.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 9V (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="44.331" upper_limit="74.302"/>
                    <measurement group_id="O2" value="69.8" lower_limit="53.875" upper_limit="82.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Responded to Each of the 3 Influenza Antigens</title>
        <description>Response to the influenza vaccine (seroconversion) was defined as &gt;= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Responded to Each of the 3 Influenza Antigens</title>
          <description>Response to the influenza vaccine (seroconversion) was defined as &gt;= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use, B (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="28.787" upper_limit="48.386"/>
                    <measurement group_id="O2" value="52" lower_limit="41.712" upper_limit="62.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, H1N1 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="50.62" upper_limit="70.305"/>
                    <measurement group_id="O2" value="63.3" lower_limit="52.925" upper_limit="72.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, H3N2 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="50.62" upper_limit="70.305"/>
                    <measurement group_id="O2" value="69.4" lower_limit="59.265" upper_limit="78.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, B (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="22.915" upper_limit="48.869"/>
                    <measurement group_id="O2" value="41.8" lower_limit="28.655" upper_limit="55.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, H1N1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="38.965" upper_limit="66.015"/>
                    <measurement group_id="O2" value="58.2" lower_limit="44.106" upper_limit="71.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, H3N2 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="44.084" upper_limit="70.857"/>
                    <measurement group_id="O2" value="65.5" lower_limit="51.419" upper_limit="77.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, B (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="27.657" upper_limit="57.85"/>
                    <measurement group_id="O2" value="65.1" lower_limit="49.073" upper_limit="78.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, H1N1 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" lower_limit="55.685" upper_limit="83.634"/>
                    <measurement group_id="O2" value="69.8" lower_limit="53.875" upper_limit="82.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, H3N2 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="48.78" upper_limit="78.132"/>
                    <measurement group_id="O2" value="74.4" lower_limit="58.828" upper_limit="86.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine</title>
        <description>Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of &gt;= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine</title>
          <description>Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of &gt;= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="67.043" upper_limit="84.305"/>
                    <measurement group_id="O2" value="91.8" lower_limit="84.547" upper_limit="96.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" lower_limit="51.131" upper_limit="77.085"/>
                    <measurement group_id="O2" value="92.7" lower_limit="82.413" upper_limit="97.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="78.779" upper_limit="97.525"/>
                    <measurement group_id="O2" value="90.7" lower_limit="77.865" upper_limit="97.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)</title>
        <description>Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)</title>
          <description>Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use, 1 (n=89,92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" lower_limit="3.61" upper_limit="6.24"/>
                    <measurement group_id="O2" value="6.83" lower_limit="4.94" upper_limit="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 14 (n=101,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="2.19" upper_limit="3.28"/>
                    <measurement group_id="O2" value="3.90" lower_limit="3.05" upper_limit="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 18C (n=101,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" lower_limit="2.52" upper_limit="3.81"/>
                    <measurement group_id="O2" value="4.82" lower_limit="3.76" upper_limit="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 19A (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.56" upper_limit="2.08"/>
                    <measurement group_id="O2" value="2.34" lower_limit="1.99" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 19F (n=102,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.71" upper_limit="2.42"/>
                    <measurement group_id="O2" value="2.89" lower_limit="2.40" upper_limit="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 23F (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.64" upper_limit="2.44"/>
                    <measurement group_id="O2" value="2.81" lower_limit="2.34" upper_limit="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 3 (n=101,94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="1.76" upper_limit="2.54"/>
                    <measurement group_id="O2" value="2.79" lower_limit="2.31" upper_limit="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 4 (n=96,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" lower_limit="2.49" upper_limit="3.86"/>
                    <measurement group_id="O2" value="5.13" lower_limit="3.94" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 5 (n=101,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.50" upper_limit="1.97"/>
                    <measurement group_id="O2" value="2.27" lower_limit="1.91" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 6B (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.61" upper_limit="2.24"/>
                    <measurement group_id="O2" value="2.56" lower_limit="2.12" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 7F (n=102,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" lower_limit="2.59" upper_limit="3.93"/>
                    <measurement group_id="O2" value="4.06" lower_limit="3.27" upper_limit="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, 9V (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" lower_limit="1.85" upper_limit="2.55"/>
                    <measurement group_id="O2" value="3.16" lower_limit="2.59" upper_limit="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 1 (n=49,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="2.77" upper_limit="5.54"/>
                    <measurement group_id="O2" value="4.51" lower_limit="3.00" upper_limit="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 14 (n=56,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" lower_limit="1.84" upper_limit="3.04"/>
                    <measurement group_id="O2" value="2.85" lower_limit="2.19" upper_limit="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 18C (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" lower_limit="2.05" upper_limit="3.41"/>
                    <measurement group_id="O2" value="3.23" lower_limit="2.45" upper_limit="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 19A (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.30" upper_limit="1.74"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.67" upper_limit="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 19F (n=57,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.51" upper_limit="2.44"/>
                    <measurement group_id="O2" value="2.29" lower_limit="1.88" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 23F (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" lower_limit="1.32" upper_limit="2.07"/>
                    <measurement group_id="O2" value="2.34" lower_limit="1.88" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 3 (n=56,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="1.39" upper_limit="2.27"/>
                    <measurement group_id="O2" value="2.43" lower_limit="1.90" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 4 (n=53,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="2.22" upper_limit="3.85"/>
                    <measurement group_id="O2" value="3.27" lower_limit="2.51" upper_limit="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 5 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="1.35" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.99" lower_limit="1.59" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 6B (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.37" upper_limit="1.88"/>
                    <measurement group_id="O2" value="2.24" lower_limit="1.79" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 7F (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="1.89" upper_limit="2.98"/>
                    <measurement group_id="O2" value="3.46" lower_limit="2.57" upper_limit="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, 9V (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.53" upper_limit="2.29"/>
                    <measurement group_id="O2" value="2.72" lower_limit="2.08" upper_limit="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 1 (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="3.85" upper_limit="9.37"/>
                    <measurement group_id="O2" value="12.04" lower_limit="7.34" upper_limit="19.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 14 (n=45,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" lower_limit="2.25" upper_limit="4.37"/>
                    <measurement group_id="O2" value="5.85" lower_limit="3.81" upper_limit="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 18C (n=44,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="2.70" upper_limit="5.35"/>
                    <measurement group_id="O2" value="8.05" lower_limit="5.37" upper_limit="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 19A (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" lower_limit="1.75" upper_limit="2.94"/>
                    <measurement group_id="O2" value="2.72" lower_limit="2.13" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 19F (n=45,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.68" upper_limit="2.85"/>
                    <measurement group_id="O2" value="3.88" lower_limit="2.78" upper_limit="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 23F (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" lower_limit="1.81" upper_limit="3.58"/>
                    <measurement group_id="O2" value="3.55" lower_limit="2.63" upper_limit="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 3 (n=45,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" lower_limit="1.98" upper_limit="3.44"/>
                    <measurement group_id="O2" value="3.37" lower_limit="2.49" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 4 (n=43,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" lower_limit="2.31" upper_limit="4.79"/>
                    <measurement group_id="O2" value="9.15" lower_limit="5.85" upper_limit="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 5 (n=44,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="1.50" upper_limit="2.29"/>
                    <measurement group_id="O2" value="2.68" lower_limit="2.04" upper_limit="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 6B (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="1.73" upper_limit="3.21"/>
                    <measurement group_id="O2" value="3.04" lower_limit="2.19" upper_limit="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 7F (n=45,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" lower_limit="3.23" upper_limit="6.60"/>
                    <measurement group_id="O2" value="5.02" lower_limit="3.65" upper_limit="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, 9V (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" lower_limit="2.03" upper_limit="3.41"/>
                    <measurement group_id="O2" value="3.83" lower_limit="2.82" upper_limit="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)</title>
        <description>GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)</title>
          <description>GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.n=participants evaluable at specified categories for each arm group.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Regardless MTX use, B (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" lower_limit="2.32" upper_limit="3.75"/>
                    <measurement group_id="O2" value="3.90" lower_limit="3.06" upper_limit="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, H1N1 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" lower_limit="4.59" upper_limit="7.95"/>
                    <measurement group_id="O2" value="9.50" lower_limit="6.76" upper_limit="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regardless MTX use, H3N2 (n=102,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.11" lower_limit="5.18" upper_limit="9.75"/>
                    <measurement group_id="O2" value="9.06" lower_limit="6.61" upper_limit="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, B (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.02" upper_limit="3.98"/>
                    <measurement group_id="O2" value="3.11" lower_limit="2.27" upper_limit="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, H1N1 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" lower_limit="3.43" upper_limit="7.00"/>
                    <measurement group_id="O2" value="7.54" lower_limit="4.80" upper_limit="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With BG MTX use, H3N2 (n=57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" lower_limit="3.88" upper_limit="8.34"/>
                    <measurement group_id="O2" value="6.04" lower_limit="4.18" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, B (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.20" upper_limit="4.40"/>
                    <measurement group_id="O2" value="5.20" lower_limit="3.57" upper_limit="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, H1N1 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" lower_limit="5.13" upper_limit="12.10"/>
                    <measurement group_id="O2" value="12.76" lower_limit="7.56" upper_limit="21.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without BG MTX use, H3N2 (n=45,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" lower_limit="5.52" upper_limit="16.09"/>
                    <measurement group_id="O2" value="15.25" lower_limit="9.06" upper_limit="25.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody</title>
        <description>Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody</title>
          <description>Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.</population>
          <units>microgram/milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="1.32" upper_limit="2.48"/>
                    <measurement group_id="O2" value="3.27" lower_limit="2.34" upper_limit="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" lower_limit="3.85" upper_limit="7.12"/>
                    <measurement group_id="O2" value="6.40" lower_limit="4.63" upper_limit="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" lower_limit="1.95" upper_limit="3.29"/>
                    <measurement group_id="O2" value="4.60" lower_limit="3.48" upper_limit="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="4.15" upper_limit="6.54"/>
                    <measurement group_id="O2" value="8.57" lower_limit="6.86" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="1.93" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.09" lower_limit="2.28" upper_limit="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="1.86" upper_limit="3.11"/>
                    <measurement group_id="O2" value="3.55" lower_limit="2.78" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.52" upper_limit="0.86"/>
                    <measurement group_id="O2" value="1.11" lower_limit="0.86" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.54" upper_limit="0.97"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.77" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" lower_limit="3.23" upper_limit="5.09"/>
                    <measurement group_id="O2" value="5.79" lower_limit="4.60" upper_limit="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.34" upper_limit="3.83"/>
                    <measurement group_id="O2" value="4.75" lower_limit="3.71" upper_limit="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.42" upper_limit="4.45"/>
                    <measurement group_id="O2" value="4.37" lower_limit="3.36" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" lower_limit="2.11" upper_limit="3.23"/>
                    <measurement group_id="O2" value="4.06" lower_limit="3.29" upper_limit="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Anti-Influenza Antibody</title>
        <description>Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
        <time_frame>Day 64 (EOS)</time_frame>
        <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
            <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Influenza and Pneumococcal Vaccine</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Anti-Influenza Antibody</title>
          <description>Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
          <population>Evaluable immunogenicity population:eligible,randomized participants;who met rheumatoid arthritis disease activity criteria;received vaccination as scheduled and &gt;=80% study drug;had pre and post-vaccination blood draw;complete set of assay results;had no major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.39" lower_limit="25.61" upper_limit="43.54"/>
                    <measurement group_id="O2" value="50.74" lower_limit="39.82" upper_limit="64.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.40" lower_limit="64.35" upper_limit="116.0"/>
                    <measurement group_id="O2" value="221.5" lower_limit="161.4" upper_limit="304.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.3" lower_limit="97.65" upper_limit="179.1"/>
                    <measurement group_id="O2" value="244.0" lower_limit="184.6" upper_limit="322.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 + Influenza and Pneumococcal Vaccine</title>
          <description>CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Influenza and Pneumococcal Vaccine</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 64, with or without background Methotrexate therapy as per local standard prescribing practice. Participants were vaccinated on Day 29 with influenza and pneumococcal vaccine based on standard practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

